UPDATED: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout

John Carroll

The big news in biopharma this weekend is the unconfirmed report that is looking to sell its generics business to Teva. But execs didn't let the headlines distract them from another goal of CEO Brent Saunders': building the pipeline.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS